All In Biotech

Free tool

FAERS Monitor: Ultiva

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020630 or its brand name (Ultiva, Remifentanil Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,419

Serious

2,326

96% of reports

Hospitalization

920

Death reported

247

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaphylactic shock370
  • hypotension166
  • anaphylactic reaction151
  • cardiac arrest122
  • blood pressure decreased105
  • bradycardia88
  • tachycardia87
  • bronchospasm78
  • rash72
  • erythema63
  • toxic epidermal necrolysis62
  • drug ineffective59
  • oxygen saturation decreased58
  • drug interaction56
  • off label use54

Reports by year received

View as table
YearReports
200426
200541
200624
200743
200867
200980
2010104
201190
2012128
2013166
2014129
2015109
2016144
201795
2018155
2019125
2020111
202198
2022151
2023149
2024126
2025131
2026126

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaphylactic shockSignal370126.6115.245,383
bronchospasmSignal7847.838.43,509
toxic epidermal necrolysisSignal6235.627.92,046
anaphylactic reactionSignal15123.820.43,279
bradycardiaSignal8814.511.81,090
blood pressure decreasedSignal10513.811.41,232
cardiac arrestSignal12212.910.81,326
oxygen saturation decreasedSignal589.07.0404
tachycardiaSignal878.56.9572
hypotensionSignal1667.26.2888
drug interactionSignal563.12.477
erythemaSignal632.72.165
rash721.41.19
off label use540.50.422
drug ineffective590.40.360

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.